Tag: M.W:400-500

1160861-53-9, Di-tert-butyl(2′,4′,6′-triisopropyl-3,6-dimethoxy-[1,1′-biphenyl]-2-yl)phosphine is a chiral-phosphine-ligands compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 307. N-(2-Methoxyphenyl)-5-methyl-2-(5-morpholin-4-yl-3,4′-bipyridin-2′-yl)-1H-imidazol-4-amine trifluoroacetate salt To a degassed mixture of 2′-(4-iodo-5-methyl-1H-imidazol-2-yl)-5-morpholin-4-yl-3,4′-bipyridine (30 mg, 0.067 mmol, from Example 257, Step 2), di-tert-butyl(2′,4′,6′-triisopropyl-3,6-dimethoxybiphenyl-2-yl)phosphine (2.0 mg, 0.0040 mmol), tBuBrettPhos Pd G3 (3.4 mg, 0.0040 mmol), and 2-methoxyaniline (9.7 muL, 0.080 mmol) in THF (0.25 mL) was added 1.0 M LHMDS (lithium bis(trimethylsilyl)amide) in THF (150 muL, 0.15 mmol). The mixture was sealed and heated at 70 C. for 2 hours. Upon cooling to room temperature, the reaction mixture was quenched by the addition of 1N HCl (1 mL). The mixture was diluted with ACN/MeOH, filtered, and purified via preparative HPLC/MS (pH 2). Yield: 8.5 mg. 1H NMR (400 MHz, d6-DMSO) delta 8.88 (d, J=5.2 Hz, 1H), 8.58-8.52 (m, 2H), 8.50 (d, J=2.2 Hz, 1H), 8.10-8.02 (m, 1H), 7.87-7.78 (m, 1H), 7.45 (br s, 1H), 7.05-6.95 (m, 1H), 6.86-6.73 (m, 2H), 6.64-6.53 (m, 1H), 3.89 (s, 3H), 3.85-3.72 (m, 4H), 3.43-3.27 (m, 4H), 2.21 (s, 3H). LCMS(M+H)+: 443.1.

1160861-53-9, The synthetic route of 1160861-53-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Incyte Corporation; Sparks, Richard B.; Shepard, Stacey; Combs, Andrew P.; Buesking, Andrew W.; Shao, Lixin; Wang, Haisheng; Falahatpisheh, Nikoo; (158 pag.)US2017/190689; (2017); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.787618-22-8,Dicyclohexyl(2′,6′-diisopropoxy-[1,1′-biphenyl]-2-yl)phosphine,as a common compound, the synthetic route is as follows.

787618-22-8, Palladium reagents -vvere synthesized following the scheme of Figure 2. Ascintillation vial (J 0 mL), equipped with a magnetic stir bar, was charged vith RuPhos (1.1equiv) or sSPhos (1.1 equiv), Ar–.X (1 equiv), and tetrahydrofuran. Solid [(1,5-COD)Pd(CH2SiMe3)2] (Vinogradova, E. V., et al. Organometallic palladium reagents forcysteine bioconjugation. Nature. 526, 687-691 (2015)) (1 1 equiv) vas added rapidly in oneportion and the resulting solution was stirred for 1 h at 1t. After this time, pentane (3 mL)was added and the resulting mixture was placed into a … 20 C freezer for 2 h. The vial wasremoved from the freezer and, in the air, the resulting precipitate was filtered, washed withpentane (5 x 3 mL), and dried under reduced pressure to afford the oxidative addition complex; Follovving the general procedure, a mixture containing 4-chlorotoluene (6.4 ~LL, 0.054mmol), RuPhos (28 mg, 0.06 mmol), and [(1,5-COD)Pd(CH2SiMe3)2] (25 mg, 0.06 nunol)was stirred at rt in a nitrogen-filled glovebox in cyclohexane (1.5 mL) for 18 h. Generalwork-up afforded A as a grey solid (37 mg, 96%,).

The synthetic route of 787618-22-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MASSACHUSETTS INSTITUTE OF TECHNOLOGY; BUCHWALD, Stephen, L.; PENTELUTE, Bradley, L.; ZHANG, Chi; (170 pag.)WO2017/151910; (2017); A2;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.564483-19-8,Di-tert-butyl(2′,4′,6′-triisopropyl-[1,1′-biphenyl]-2-yl)phosphine,as a common compound, the synthetic route is as follows.

564483-19-8, General procedure: [(crotyl)PdCl]2 (197 mg, 0.50 mmol); 22 AgOTf (257 mg, 1.00 mmol); 27 tBuXPhos (425 mg, 1.00 mmol); 2-MeTHF (10.0 mL); 2 h. Product obtained as a slightly yellow solid (722 mg, 98%); The spectral properties are complicated due to the presence of isomers. 1H NMR (400 MHz, CDCl3, delta): Complex spectrum, see FIG. 1; 13C NMR (100 MHz, CDCl3, delta): 153.4, 152.3, 152.0, 146.4, 146.2, 146.0, 145.8, 144.1, 135.0, 134.9, 134.7, 134.4, 134.1, 133.7, 133.6, 133.3, 133.2, 131.5 (2 peaks), 131.4 (2 peaks), 128.1 (2 peaks), 128.0, 127.1, 126.1, 125.7, 124.6, 124.1, 122.9, 122.8, 122.5, 121.7, 121.4, 119.3, 112.9 (2 peaks), 48.3, 38.9, 38.8, 38.3, 38.1, 37.5, 37.3, 33.8, 33.5, 32.0, 31.9, 31.7, 31.6, 31.3, 31.1 (2 peaks), 31.0 (2 peaks), 30.7 (2 peaks), 26.2, 25.6, 25.5, 25.4, 25.1, 24.9, 24.3, 24.2, 24.0 (2 peaks), 23.7, 23.4, 22.8, 16.4 (2 peaks) [Observed complexity due to C-F and C-P coupling]; 19F NMR (372 MHz, CDCl3, delta): -77.9 (s, 3F); 31P NMR (162 MHz, CDCl3, delta): 72.2, 71.7, 66.7; Anal. calcd. for C34H52O3F3PSPd: C, 55.54; H, 7.13. Found C, 55.66; H, 6.99.

564483-19-8 Di-tert-butyl(2′,4′,6′-triisopropyl-[1,1′-biphenyl]-2-yl)phosphine 11618717, achiral-phosphine-ligands compound, is more and more widely used in various fields.

Reference£º
Patent; Johnson Matthey Public Limited Company; Colacot, Thomas; Jon Deangelis, Andrew; (66 pag.)US9777030; (2017); B2;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.6737-42-4,1,3-Bis(diphenylphosphino)propane,as a common compound, the synthetic route is as follows.

6737-42-4, Ethyl-2,2,4,4-tetramethyl chroman-6-carboxylate (Compound 23) A solution of 6-bromo-2,2,4,4-tetramethylchroman (synthesis is described in U.S. Pat. No. 6,252,090)(2.2 g, 8.08 mmol), palladium acetate (0.145 g, 0.65 mmol) and 1,3-bis(diphenylphosphino)propane (0.267 g, 0.65 mmol) in a mixture of N,N-dimethylformamide (25 mL), ethanol (20 mL) and triethyl amine (7 mL) was heated at 90 C. under an atmosphere of carbon monoxide overnight. The volatiles were distilled off in vacuo and the residue was diluted with water and extracted with ethyl acetate. The combined organic extract was washed with brine (*1), dried over anhydrous magnesium sulfate, filtered and evaporated in vacuo to an oil which was subjected to flash column chromatography over silica gel (230-400 mesh) using 5-10% ethyl acetate in hexane as the eluent to afford the title compound (1.9 g, 90%). 1H NMR (300 MHz, CDCl3): delta8.00 (d, 1H, J=2.3 Hz), 7.76 (dd, 1H, J=2.1, 8.5 Hz), 6.79 (d, 1H, J=8.5 Hz), 4.33 (q, 2H, J=7.1 Hz), 1.85 (s, 2H), 1.36 (s, 6H), 1.37 (s, 6H), 1.39-1.33 (m, 3H).

6737-42-4 1,3-Bis(diphenylphosphino)propane 81219, achiral-phosphine-ligands compound, is more and more widely used in various fields.

Reference£º
Patent; Vasudevan, Jayasree; Wang, Liming; Liu, Xiaoxia; Tsang, Kwok-Yin; Yuan, Yang-Dar; Chandraratna, Roshantha A.; US2003/207937; (2003); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.564483-19-8,Di-tert-butyl(2′,4′,6′-triisopropyl-[1,1′-biphenyl]-2-yl)phosphine,as a common compound, the synthetic route is as follows.

Example 537 26 mg of 5-hydroxy-1-methyl-1H-indole, 64 mg of tripotassium phosphate, 3.8 mg of 2-(di-tert-butylphosphino)-2′,4′,6′-triisopropylbiphenyl and 5.5 mg of tris(dibenzylideneacetone)dipalladium(0) were added to 1.0 mL of toluene solution containing 50 mg of methyl 2-(benzamido)-4-bromobenzoate at room temperature, and the resulting mixture was heated to reflux under nitrogen atmosphere for 2 hours. After the reaction mixture was cooled to room temperature, ethyl acetate and 10% citric acid aqueous solution were added and insoluble were removed by filtration. The organic layer was separated and dried over anhydrous magnesium sulfate after washed with a saturated sodium chloride aqueous solution, and the solvent was evaporated under reduced pressure. The obtained residue was purified with silica gel column chromatography [PSQ100B (spherical) manufactured by Fuji Silysia Chemical Ltd., eluent; hexane: ethyl acetate = 5:1] to obtain 53 mg of methyl 2-(benzamido)-4-(1-methyl-1H-indol-5-yloxy)benzoate as pale yellow solid. 1H-NMR (CDCl3) delta: 3.83 (3H, s), 3.93 (3H, s), 6.47 (1H, dd, J = 3.1, 0.9 Hz), 6.63 (1H, dd, J = 9.0, 2.6 Hz), 7.02 (1H, dd, J = 8.8, 2.2 Hz), 7.10 (1H, d, J = 2.9 Hz), 7.32-7.38 (2H, m), 7.47-7.57 (3H, m), 7.97-8.03 (3H, m), 8.58 (1H, d, J = 2.6 Hz), 12.14 (1H, s)., 564483-19-8

The synthetic route of 564483-19-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; TOYAMA CHEMICAL CO., LTD.; EP1820795; (2007); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13991-08-7,1,2-Bis(diphenylphosphino)benzene,as a common compound, the synthetic route is as follows.

45.6mg mesityl -Cu and 3ml of toluene were added to 48.5mg (0.25mmol) of 7-PyIn and 111.5mg (0.25 mmol) of dppb in a glove box. It forms ayellow solution. It was filtered and coated with a layer of hexane. It formsorange-red crystals. Under UV (356nm), they emit light in a strong orange.Yield: 71%., 13991-08-7

As the paragraph descriping shows that 13991-08-7 is playing an increasingly important role.

Reference£º
Patent; MERCK PATENTGMBH; WESEMANN, LARS; KLEIH, MATTHIAS; MAYER, HERMANN, AUGUST; (72 pag.)JP2016/501830; (2016); A;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.19845-69-3,1,6-Bis(diphenylphosphino)hexane,as a common compound, the synthetic route is as follows.

General procedure: [Cu(CH3CN)4][ClO4] (65.2mg, 0.200mmol) was added to a degassed DCM solution (about 10mL) of BrbpyBr (62.4mg, 0.200mmol) and dppm (78.4mg, 98%, 0.200mmol). The color of the solution gradually changed to pale yellow. The solution was then stirred for 5h at room temperature. After filtration, layering n-hexane onto the DCM solution gave the product as pale yellow crystals., 19845-69-3

19845-69-3 1,6-Bis(diphenylphosphino)hexane 2754312, achiral-phosphine-ligands compound, is more and more widely used in various fields.

Reference£º
Article; Li, Xiu-Ling; Xin, Xue-Lian; Ai, Yu-Bo; Tan, Ming; Lu, Han; Du, Bai-Xiang; Inorganica Chimica Acta; vol. 401; (2013); p. 58 – 63;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.19845-69-3,1,6-Bis(diphenylphosphino)hexane,as a common compound, the synthetic route is as follows.

1,6-bis (diphenylphosphino) hexane (1.37 g, 3 mmol),10- (4-bromophenoxy) decanol (3.9 g, 12 mmol),Ethylene glycol 10mL and nickel bromide 50mg added to a 50mL three-necked flask and purged with nitrogen,The temperature was raised to 180 C.After 4h magnetic stirring reaction system,After cooling, all the reactants were dissolved in 20 mL of dichloromethane,The organic layer was washed three times with deionized water.After the solution was dried over anhydrous Na2SO4 filtered,The organic phase was washed with a large amount of ether and a large amount of tetrahydrofuran respectively,Compound B3 is then obtained., 19845-69-3

The synthetic route of 19845-69-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Beijing University of Chemical Technology; Wang Zhongming; Yang Qian; Han Kefei; Zhu Hong; (9 pag.)CN107347909; (2017); A;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1160861-53-9,Di-tert-butyl(2′,4′,6′-triisopropyl-3,6-dimethoxy-[1,1′-biphenyl]-2-yl)phosphine,as a common compound, the synthetic route is as follows.

A dry Schlenk flask is charged with 183 mg (0.50 mmol) of [(allyl)PdCl]2 and 257 mg (1.0 mmol) of silver trifluoromethanesulfonate. A second dry Schlenk flask is fitted with a Schlenk frit and is charged with 485 mg (1.0 mmol) of tBuBrettPhos. The flasks are evacuated and backfilled with nitrogen. This evacuation/backfill cycle was repeated a total of three times. 10 mL of anhydrous THF is added to the first flask and the mixture is stirred for 30 min at room temperature (rt) while protecting from light. The mixture from flask one is then transferred via cannula through the Schlenk frit into the second flask to remove the AgCl. The frit is rinsed with an additional 10 mL of anhydrous THF. The mixture is stirred at room temperature for 2 hours, followed by the slow addition of 30 mL of hexanes to obtain a pale yellow precipitate. It is filtered, washed (2*10 mL of hexanes) and dried in vacuo to give 653 mg (0.84 mmol, 84%) of analytically pure (pi-allyl)Pd(tBuBrettPhos)OTf as a slightly yellow solid; 1H NMR (400 MHz, CDCl3, delta): 7.45 (d, J=1.8 Hz, 1H), 7.28 (d, J=1.7 Hz, 1H), 7.07 (dd, J=2.9 Hz, 9.0 Hz, 1H), 6.96 (dd, J=2.9 Hz, 8.9 Hz, 1H), 5.52 (sept, J=7.1 Hz, 1H), 4.39 (app d, J=6.3 Hz, 1H), 3.83 (s, 3H), 3.35 (dd, J=9.2 Hz, 13.9 Hz, 1H), 3.32 (s, 3H), 2.97 (sept, J=6.9 Hz, 1H), 2.78 (app d, J=12.4 Hz, 1H), 2.54 (sept, J=6.7 Hz, 1H), 2.30-1.12 (m, 2H), 1.45-1.27 (m, 24H), 1.24 (dd, J=6.9 Hz, 11.8 Hz, 6H), 0.87 (d, J=6.9 Hz, 3H), 0.70 (d, J=6.9 Hz, 3H); 13C NMR (100 MHz, CDCl3, delta): 156.3, 154.6 (2 peaks), 154.5, 152.2, 151.5, 136.5, 136.2, 125.8, 125.7, 125.6, 125.4, 125.2, 122.6, 119.7, 119.6, 119.4, 116.2, 115.5 (2 peaks), 112.8 (2 peaks), 112.0 (2 peaks), 99.8, 99.5, 58.4 (2 peaks), 54.7, 54.6, 39.9, 39.8, 39.3, 39.1, 34.0, 32.1, 32.0, 31.9, 31.7, 31.6 (2 peaks), 25.7, 25.5, 24.6, 24.5, 24.2 [Observed complexity due to C-F and C-P coupling]; 19F NMR (372 MHz, CDCl3, delta): -77.9 (s, 3F); 31P NMR (162 MHz, CDCl3, delta): 86.2; Anal. calcd. for C35H54O5F3PSPd: C, 53.81; H, 6.97. Found C, 53.81; H, 7.10., 1160861-53-9

As the paragraph descriping shows that 1160861-53-9 is playing an increasingly important role.

Reference£º
Patent; Johnson Matthey Public Limited Company; Colacot, Thomas; Jon Deangelis, Andrew; (66 pag.)US9777030; (2017); B2;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.564483-18-7,2-(Dicyclohexylphosphino)-2′,4′,6′-tri-i-propyl-1,1′-biphenyl,as a common compound, the synthetic route is as follows.

564483-18-7, Example 58A 3-Fluoro-N-(2-fluoro-4-nitrophenyl)-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridine-4-amine A solution of 20 mg (0.06 mmol) of 4-chloro-3-fluoro-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridine, 11.5 mg (0.074 mmol) of 2-fluoro-4-nitroaniline, 5.6 mg (0.006 mmol) of tris(dibenzylideneacetone)dipalladium, 5.8 mg (0.012 mmol) of dicyclohexyl(2′,4′,6′-triisopropyl-biphenyl-2-yl)phosphine and 12.7 mg (0.09 mmol) of potassium carbonate in 1.00 ml of degassed tert-butanol is stirred in a sealed pressure vessel at 100 C. for 3 h. After cooling to RT, the reaction mixture is filtered through kieselguhr, the kieselguhr is washed with ethyl acetate and the solvent is removed from the filtrate. The residue is purified by preparative HPLC. Yield: 21.5 mg (67% of theory) LC-MS (Method 1): Rt=2.56 min. MS (ESI pos.): m/z=445 (M+H)+.

As the paragraph descriping shows that 564483-18-7 is playing an increasingly important role.

Reference£º
Patent; Bayer HealthCare AG; US2008/269268; (2008); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate